Production of many medical radioisotopes takes place in research reactors, which are experiencing ageing issues
The HSC said the radionuclide and radiopharmaceutical supply chain was inherently complex and fragile. Courtesy NRG Pallas.
Europe’s medical radionuclide and radiopharmaceutical supply chain is vulnerable due to limited production facilities and distribution challenges and must be strengthened to maximise its full potential, a position paper from the European Nuclear Society’s (ENS) High Scientific Council (HSC) has found.
What we offer
Independent news and information for and about the global nuclear industry
For nuclear incidents, NucNet operates 24 hours a day, 7 days a week
Daily, weekly and monthly newsletters
Access to infographics for subscribers to use in their own editorial and marketing material
Exclusive analysis and special reports on key nuclear industry topics
Breaking news on social media
Access to the ‘NucNet Style Guide for Nuclear Reporters and Communicators’
Access to NucNet editorial database containing more than 18,000 news articles and features from January 1991
A reliable media and communications partner for the nuclear energy industry. Distribution of your industry news stories
Manage your own preferences
Get involved. Members can attend meetings and be part of NucNet’s policy and editorial decision-making